Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)


This phase II trial tests whether atezolizumab and bevacizumab after Y-90 TARE works to shrink tumors in patients with hepatocellular (liver) cancer that cannot be removed by surgery (unresectable). Transarterial radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed the tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Adding atezolizumab and bevacizumab after Y90 TARE may prevent liver cancer from returning for a longer period.
Goff, Laura

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: